Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
5.30 -0.02 (-0.38%) 03/07/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 5.30 unch (unch) 19:35 ET
Quote Overview for Fri, Mar 7th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
5.26
Day High
5.48
Open 5.37
Previous Close 5.32 5.32
Volume 2,630,000 2,630,000
Avg Vol 3,643,285 3,643,285
Stochastic %K 30.22% 30.22%
Weighted Alpha -34.07 -34.07
5-Day Change -0.06 (-1.12%) -0.06 (-1.12%)
52-Week Range 4.32 - 9.33 4.32 - 9.33
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,263,287
  • Shares Outstanding, K 238,356
  • Annual Sales, $ 333,620 K
  • Annual Income, $ -39,140 K
  • EBIT $ -28 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.87
  • Price/Sales 3.80
  • Price/Cash Flow N/A
  • Price/Book 7.27

Options Overview Details

View History
  • Implied Volatility 68.87% ( -0.55%)
  • Historical Volatility 65.83%
  • IV Percentile 33%
  • IV Rank 39.02%
  • IV High 156.43% on 03/11/24
  • IV Low 12.86% on 06/10/24
  • Put/Call Vol Ratio 0.52
  • Today's Volume 214
  • Volume Avg (30-Day) 2,726
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 85,214
  • Open Int (30-Day) 86,730

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.10
  • Number of Estimates 7
  • High Estimate -0.04
  • Low Estimate -0.15
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.84 +9.62%
on 02/24/25
Period Open: 5.58
6.55 -19.08%
on 02/19/25
-0.28 (-5.02%)
since 02/07/25
3-Month
4.32 +22.69%
on 12/18/24
Period Open: 5.72
6.55 -19.08%
on 02/19/25
-0.42 (-7.34%)
since 12/06/24
52-Week
4.32 +22.69%
on 12/18/24
Period Open: 8.97
9.33 -43.19%
on 05/07/24
-3.67 (-40.91%)
since 03/07/24

Most Recent Stories

More News
Tenapanor Approved in China for Hyperphosphatemia

ARDX : 5.30 (-0.38%)
Ardelyx to Participate in Upcoming Investor Conferences

ARDX : 5.30 (-0.38%)
Ardelyx Stock Rises After-Hours On Q4 Beat, Drug Sales Outlook: Retail Gets Big Dose Of Optimism

Revenue for the quarter was $116.13 million, topping the consensus estimate of $111.16 million, driven by robust sales of its two approved drugs, Ibsrela and Xphozah.

VTI : 283.34 (+0.47%)
ARDX : 5.30 (-0.38%)
IWM : 205.95 (+0.33%)
XBI : 87.30 (+0.28%)
Ardelyx Tops Estimates as Sales Surge

The biopharma reported strong revenue growth in the fourth quarter thanks to solid performances from both of its approved products, Ibsrela and Xphozah.

ARDX : 5.30 (-0.38%)
Ardelyx: Q4 Earnings Snapshot

Ardelyx: Q4 Earnings Snapshot

ARDX : 5.30 (-0.38%)
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

ARDX : 5.30 (-0.38%)
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference

ARDX : 5.30 (-0.38%)
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

ARDX : 5.30 (-0.38%)
Ardelyx Provides Update on Increasing Commercial Momentum and 2025 Strategic Priorities

ARDX : 5.30 (-0.38%)
Ardelyx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ARDX : 5.30 (-0.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

3rd Resistance Point 5.64
2nd Resistance Point 5.56
1st Resistance Point 5.43
Last Price 5.30
1st Support Level 5.22
2nd Support Level 5.13
3rd Support Level 5.00

See More

52-Week High 9.33
Fibonacci 61.8% 7.42
Fibonacci 50% 6.82
Fibonacci 38.2% 6.23
Last Price 5.30
52-Week Low 4.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
How to Trade Futures Spreads Like a Pro – Unlock Powerful Market Insights